So-called 'synthetic marijuana' linked to serious health problems

February 2, 2017

Synthetic marijuana compounds are marketed as safe, legal alternatives to marijuana that cannot be detected by standard drug testing, but these substances differ chemically from marijuana; are linked to dangerous side effects, including seizures, psychosis, dependence, and death; and are not safe substitutes, say University of Arkansas for Medical Sciences (UAMS) scientists in a Review published February 2 in Trends in Pharmacological Sciences.

Researchers discovered several decades ago that the primary psychoactive compound in marijuana, Δ9-THC, activates two receptors, CB1, found in high abundance in the brain and central nervous system, and CB2, found primarily in the immune system. To study these receptors, researchers identified other naturally occurring chemicals and developed synthetic cannabinoid (SCB) compounds that also bind to them; collectively, these compounds are known as cannabinoids. Although they activate the CB1 and CB2 receptors, SCBs and other cannabinoids are otherwise chemically distinct from marijuana and often from each other.

SCBs are now marketed and sold as synthetic marijuana under names such as "K2" and "Spice." "It started in the early 2000s in Europe, and in the U.S., in 2007 or so, we started seeing all kinds of people coming into emergency rooms saying they smoked marijuana, but then they had these really bizarre symptoms that did not correspond with the effects you see with marijuana," says Paul L. Prather, a cellular and molecular pharmacologist at UAMS.

SCBs are often sold as safe alternatives to marijuana that, because of their chemical structures, will not be discovered through standard drug screenings. This feature makes them popular among groups who want to elude detection, such as adolescents and military personnel. SCBs are also more potent than Δ9-THC; "these are highly efficacious drugs; they tend to activate the CB1 receptor to a greater degree than we can ever get to with THC from marijuana," says William E. Fantegrossi, a behavioral pharmacologist at UAMS. As a result, some users turn to them to achieve a more intense high.

A range of both acute and long-term adverse effects of SCB use are reported in clinical case studies, including seizures and convulsions, kidney injury, cardiotoxicity, strokes, anxiety, and psychosis in susceptible individuals, as well as tolerance, withdrawal, and dependence. Twenty deaths have also been linked to SCB use.

Prather and his co-authors note that in addition to the efficacy of SCBs in activating the CB1 receptors, they pose other health risks. Since they are chemically distinct from Δ9-THC, there is a chance that they may be activating other cellular receptors in addition to CB1 and that these receptors could be responsible for some of the seen in SCB users.

Another risk is that users purchasing these drugs over the internet or elsewhere simply do not know what they are getting in each purchase. "Not only does the amount of the active pharmacological agent change with different batches of drugs, made by different labs, but the active compound itself can change,"says Fantegrossi. "And there are usually a minimum of three, if not five, different synthetic cannabinoids in a single product," adds Prather.

The authors caution against dismissing the therapeutic potential of cannabinoids entirely, noting that just as with opioids, improper use or abuse can lead to adverse effects or death, but proper use can provide significant benefits. But Prather cautions that "the public sees anything with the marijuana label as potentially safe, but these synthetic compounds are not , ... you never know what they are, and they are not safe."

Explore further: Synthetic cannabinoids versus natural marijuana—a comparison of expectations

More information: Trends in Pharmacological Sciences, Ford, et al., "Synthetic Pot: Not Your Grandfather's Marijuana" http://www.cell.com/trends/pharmacological-sciences/fulltext/S0165-6147(16)30185-7 , DOI: 10.1016/j.tips.2016.12.003

Related Stories

Synthetic cannabinoids versus natural marijuana—a comparison of expectations

April 27, 2016
An article entitled "Comparison of Outcome Expectancies for Synthetic Cannabinoids and Botanical Marijuana," from The American Journal of Drug and Alcohol Abuse, studied the expected outcomes of both synthetic and natural ...

Marijuana compounds show promise in treatment of cardiac disease

January 16, 2017
A Nevada company is hoping to develop new medicines for heart failure using compounds in marijuana and a novel therapy identified by a University of Hawaiʻi at Mānoa researcher.

Medical marijuana helpful for cancer-linked symptoms

December 18, 2014
(HealthDay)—Cannabis and cannabinoid pharmaceuticals can be helpful for nausea and vomiting, pain, and weight loss associated with cancer, according to research published online Dec. 10 in CA: A Cancer Journal for Clinicians.

A look at the growing use of synthetic drugs

March 6, 2015
In recent years, hundreds of new synthetic recreational drugs have emerged – drugs that neither the general public nor the scientific community know very much about. Many of these new synthetic drugs – often referred ...

Recommended for you

One in 4 women and 1 in 6 men aged 65+ will be physically disabled in Europe by 2047

October 23, 2017
By 2047 one in four women and one in six men aged 65 and above is expected to be living with a physical disability that will severely restrict everyday activities, reveals an analysis published in the online journal BMJ Open.

Protein regulates vitamin A metabolic pathways, prevents inflammation

October 23, 2017
A team of researchers from Case Western Reserve University School of Medicine have discovered how uncontrolled vitamin A metabolism in the gut can cause harmful inflammation. The discovery links diet to inflammatory diseases, ...

New insights into controversial diagnosis of adolescent chronic fatigue

October 23, 2017
Crucial new research could provide some clarity around the controversy surrounding the diagnosis and treatment of chronic fatigue syndrome (CFS) in adolescents. The research by the Murdoch Children's Research Institute published ...

Do boys really have a testosterone spurt at age four?

October 23, 2017
The idea that four-year-old boys have a spurt of testosterone is often used to explain challenging behaviour at this age.

Our laws don't do enough to protect our health data

October 23, 2017
Have you ever wondered why your computer often shows you ads that seem tailor-made for your interests? The answer is big data. By combing through extremely large datasets, analysts can reveal patterns in your behavior.

New prevention exercise programme to reduce rugby injuries

October 23, 2017
A new dynamic 20-minute exercise programme, performed by rugby players before training and pre-match, could dramatically reduce injuries in the sport according to a benchmark study published today (Sunday 22 October).

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.